US-German partnership hopes BNT327 will compete with Merck’s bestseller Keytruda
Pharma group estimates Camizestrant could be worth up to $5bn of sales in its peak year
If successful, it would be the first new class of drug against certain bacteria strains for more than 50 years
The Enhanced Games spotlight a growing interest in drugs not only to improve performance, but also to treat depression
Companies riding on one big idea should use the good times to plan their next move
New schemes seek to attract international talent and lock in funding security for researchers
Child suffering from rare liver disease shows improved health after treatment
Danish company has had some poor results for new drugs designed to replace treatments when they go off patent
Initiative backed by £50mn in government money comes as US administration seeks to cut funding and suppress research
Novartis and Sanofi CEOs push for European benchmark against US prices
Swiss group becomes latest pharmaceutical company to promise investment in the face of potential tariffs
Alis Biosciences then plans to list and offer big investors an easy way to spread their bets
Promising late-stage trial results lift US pharmaceutical group’s shares almost 15%
US pharmaceutical group says patient in study experienced ‘potential drug-induced liver injury’
Move comes as government seeks to boost UK’s standing as drugs research leader
Letting software and life sciences companies emerge from research has long-term benefits for academic institutions
Acquisitions hold cure for pharma companies’ chronic patent cliff problem
AI unit is boosted by first external funding round led by OpenAI-backer Thrive Capital
Lack of incentives is driving down the number of clinical researchers in Britain
Machine makes 3D scans of the digestive system, which could improve early diagnosis for the second-deadliest cancer
The health benefits could be so extreme that it upends the annuity market, hitting retirement incomes and insurers
London-listed drugmaker will establish research centre in Beijing
Academic institutions have frozen new hires and limited PhD places
Cambridge university among institutions seeing chance to hire talent unsettled by US spending cuts
Pharmaceutical groups are rushing to dominate market that will grow to 900mn people by 2030
